


## Erythromycin lactobionate

## Chemical Properties

CAS No. :	3847-29-8
Formula:	C <sub>49</sub> H <sub>89</sub> N <sub>5</sub> O <sub>25</sub>
Molecular Weight:	1092.233
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.[1] It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).[2] Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.[3],[4] Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.[5],[6]
Targets(IC50)	Others,Antibacterial,Antibiotic,DNA/RNA Synthesis

## Solubility Information

Solubility	H <sub>2</sub> O: 1 mg/mL (0.92 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.9156 mL	4.5778 mL	9.1556 mL
5 mM	0.1831 mL	0.9156 mL	1.8311 mL
10 mM	0.0916 mL	0.4578 mL	0.9156 mL
50 mM	0.0183 mL	0.0916 mL	0.1831 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Wilson, D.N. The A-Z of bacterial translation inhibitors. *Crit. Rev. Biochem. Mol. Biol.* 44(6), 393-433 (2009).
- Kanatani, M.S., and Guglielmo, B.J. The new macrolides. Azithromycin and clarithromycin. *Western J. Med.* 160(1), 31-37 (1994).
- Westphal, J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. *Br. J. Clin. Pharmacol.* 50(4), 285-295 (2000).
- Bibi, Z. Role of cytochrome P450 in drug interactions. *Nutr. Metab. (Lond)* 5(27), 1-10 (2008).
- Hirakata, Y., Kaku, M., Tomono, K., et al. Efficacy of erythromycin lactobionate for treating *Pseudomonas aeruginosa* bacteremia in mice. *Antimicrobial Agents and Chemotherapy* 36(6), 1198-1203 (1992).
- Austin, K.L., Mather, L.E., Philpot, C.R., et al. Intersubject and dose-related variability after intravenous administration of erythromycin. *British Journal of Clinical Pharmacology* 10(3), 273-279 (1980).

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481